Search PubMed⌕ Search

Biomedical subjects

H Fernandez

Publications and source records attributed to H Fernandez.

At least 289 records · Page 16Linked to original sources

Molecular forms of acetylcholinesterase in pineal cell and sympathetic neuronal cultures.

The activities of the various molecular forms of acetylcholinesterase (AChE) were measured in monolayer cultures of neonatal rat pineal cells grown alone and in co-culture with sympathetic neurons. AChE forms characterized by sedimentation coefficients of 4S, 6.5S, and 10S were found in he neuronal and pineal cultures, as well as in the co-cultures. The 16S AChE form was found only in the neuronal cultures. Total AChE activity increased with culture age in the co-cultures, but it decreased in pineal cells cultured alone. The low level of activity present in the neuronal cultures did not change markedly over the 27-day culture period. These results, which show bidirectional neuron-pineal cell effects, suggest that AChE molecular forms may be important markers to study the mechanisms underlying neuron-target cell interaction in the developing sympathetic nervous system.

Acetylcholinesterase↗

Clinical efficacy of ribavirin in the treatment of genital herpes simplex virus infection.

48 patients participated in a double-blind placebo-controlled study conducted to evaluate the efficacy of ribavirin in the treatment of herpes simplex virus genital infection. Study design did not allow a conclusion regarding usefulness of the drug in preventing recurrences. Ribavirin treatment (800 mg/day p.o) for 10 days reduced disease severity and promoted recovery as compared with placebo treatment.

Clinical Trials as Topic↗

Somatosensory central latencies and disc discrimination in multiple sclerosis.

1. Somatosensory evoked potentials are abnormal in a large percentage of patients with severe multiple sclerosis if amplitude, latency and right-left asymmetry are all considered. Mild disease has remained difficult to identify. This screening test employing two stimulus sites in the same arm did not improve the yield. 2. Stimulation of the median nerve at the elbow is not often likely to justify the associated discomfort, except in patients with known disease in the forearm. 3. Measuring the central conduction velocities from easily recorded low cervical potentials up to the parietal scalp deflections eliminates the need to consider the length and health of the peripheral nerve stimulated. 4. Central conduction velocities were not significantly related to age or total body height in this population. Extremely old or tall subjects may still deserve special consideration if the cervical responses are truly nerve propagated waves. 5. One restricted measure of stereogno-sis--disc size discrimination, correlated well with conduction times from the low cervical region to short-latency deflections in the post-central parietal area, but patients with delayed onset of deflections still maintained normal interpeak latencies. 6. more precise correlations between components of stereognosis, and the integrity of mediating neurons, will be possible when the electrical generators of the SER are better delineated.

Aging↗

New systems for a two-speed electroencephalograph with an auditory device for diminishing the length of seizures.

The author describes a system for testing patients with petit mal seizures. The system has the following advantages: 1) EEG paper speed is automatically increased from 2.5 mm/s to 25 mm/s when brainwave activity increases, with the increased speed maintainable for up to 4.0 sec after the last seizure burst. Control studies with constant speed and two-speed systems operating simultaneously demonstrate that no significant distortion occurs at the moment of change in speed. The convenience of handling a greatly reduced volume of paper is obvious. 2) An auditory stimulus, either a pure tone burst of 1000 HZ or loud music, is also triggered by an increase in amplitude of brainwave activity. Testing of 15 patients shows a significant decrease (p less than 0.01) in duration of seizure activity when the stimulus is activated.

Acoustic Stimulation↗

Disposition of a new rate-controlled formulation of prazosin in the treatment of hypertension during pregnancy: transplacental passage of prazosin.

Prazosin (PRZ) in conventional tablet form (P-CT) has the disadvantages of a relatively short terminal half-life, a slight solubility in water and the well-recognized adverse effect of symptomatic orthostatic hypotension. The pharmacokinetic study of a new rate-controlled formulation of prazosin (Prazosin-Gastrointestinal System: P-GS) was performed in 9 pregnant women during the third trimester of pregnancy. Patients had persistent elevation of blood pressure. The subjects gave their informed consent for oral administration of 1 daily dose of 5 mg P-GS at 8 a.m. A first analysis period on day 1 enabled definition of the initial pharmacokinetic behavior of the drug, while the aim of a second was to evaluate its fate at plateau. The clinical course of both mother and fetus was subsequently monitored. This was an open, non-randomized study, each patient serving as her own control. For 3 patients, we aimed to determine the possible transplacental passage of PRZ at delivery. PRZ levels were measured by HPLC and data were analysed by noncompartmental linear pharmacokinetic methods. The data show: (i) P-GS was well tolerated by all patients and there were no significant changes in fetal heart rate during the study. (ii) A significant decrease in diastolic blood pressure was observed after the 36th hour following the first dose of P-GS while a reduction in systolic blood pressure was observed on day 4. (iii) An approximated relative bioavailability (f'P-GS) of 36.5% was calculated. P-GS appears to have a lower bioavailability than P-CT in women of similar gestational age. (iv) Both Cmax and AUC0-->infinity are significantly increased at plateau. Further, terminal half-life is increased with regard to the value determined with P-CT. No accumulation of PRZ was noted at steady-state. (v) P-GS is an example of an oral zero-order absorption product that offers one approach to control and improve the outcome of hypertensive therapy during pregnancy. This treatment could represent an alternative to methyldopa as a first treatment of pregnancy-associated hypertension. (vi) There is a slight transplacental passage of the drug (of the order of 10-20%).

Adrenergic alpha-Antagonists↗